- Home
- ZYME vs NXP Comparison
ZYME vs NXP Comparison
Compare ZYME & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- NXP
- Stock Information
- Founded
- ZYME 2003
- NXP 1992
- Country
- ZYME United States
- NXP United States
- Employees
- ZYME N/A
- NXP N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- NXP Trusts Except Educational Religious and Charitable
- Sector
- ZYME Health Care
- NXP Finance
- Exchange
- ZYME Nasdaq
- NXP Nasdaq
- Market Cap
- ZYME 846.1M
- NXP 730.9M
- IPO Year
- ZYME 2017
- NXP N/A
- Fundamental
- Price
- ZYME $11.31
- NXP $14.23
- Analyst Decision
- ZYME Buy
- NXP
- Analyst Count
- ZYME 6
- NXP 0
- Target Price
- ZYME $19.50
- NXP N/A
- AVG Volume (30 Days)
- ZYME 553.2K
- NXP 70.0K
- Earning Date
- ZYME 05-08-2025
- NXP 01-01-0001
- Dividend Yield
- ZYME N/A
- NXP 4.04%
- EPS Growth
- ZYME N/A
- NXP N/A
- EPS
- ZYME N/A
- NXP 0.54
- Revenue
- ZYME $93,384,000.00
- NXP N/A
- Revenue This Year
- ZYME $26.29
- NXP N/A
- Revenue Next Year
- ZYME $75.78
- NXP N/A
- P/E Ratio
- ZYME N/A
- NXP $26.81
- Revenue Growth
- ZYME 85.05
- NXP N/A
- 52 Week Low
- ZYME $8.21
- NXP $12.91
- 52 Week High
- ZYME $17.70
- NXP $14.89
- Technical
- Relative Strength Index (RSI)
- ZYME 40.96
- NXP 61.64
- Support Level
- ZYME $10.86
- NXP $13.78
- Resistance Level
- ZYME $13.23
- NXP $14.33
- Average True Range (ATR)
- ZYME 0.56
- NXP 0.15
- MACD
- ZYME -0.10
- NXP 0.06
- Stochastic Oscillator
- ZYME 18.78
- NXP 86.49
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a diversified closed-end investment company. It seeks to provide current income and stable dividends, exempt from regular federal and designated state income taxes, consistent with the preservation of capital by investing primarily in a portfolio of municipal obligations.